Shares of Inogen Inc (NASDAQ:INGN) have earned a consensus rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $105.20.
A number of equities analysts recently weighed in on INGN shares. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $128.00 price target for the company in a research report on Tuesday, January 9th. BidaskClub upgraded Inogen from a “hold” rating to a “buy” rating in a research report on Saturday, February 10th.
In related news, EVP Alison Bauerlein sold 15,911 shares of the stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $124.48, for a total value of $1,980,601.28. Following the completion of the transaction, the executive vice president now owns 20,072 shares in the company, valued at approximately $2,498,562.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Scott Wilkinson sold 30,651 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $115.75, for a total value of $3,547,853.25. Following the completion of the transaction, the insider now owns 38,107 shares of the company’s stock, valued at approximately $4,410,885.25. The disclosure for this sale can be found here. Insiders sold a total of 156,869 shares of company stock valued at $18,718,250 in the last quarter. 5.31% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in INGN. BlackRock Inc. boosted its position in Inogen by 4.0% during the 4th quarter. BlackRock Inc. now owns 2,306,534 shares of the medical technology company’s stock worth $274,662,000 after acquiring an additional 87,737 shares during the period. Rock Springs Capital Management LP acquired a new stake in Inogen during the 4th quarter worth about $9,526,000. Fuller & Thaler Asset Management Inc. acquired a new stake in Inogen during the 4th quarter worth about $8,858,000. Prudential Financial Inc. boosted its position in Inogen by 78.2% during the 3rd quarter. Prudential Financial Inc. now owns 124,088 shares of the medical technology company’s stock worth $11,801,000 after acquiring an additional 54,467 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in Inogen during the 4th quarter worth about $5,874,000. Hedge funds and other institutional investors own 99.46% of the company’s stock.
Inogen (NASDAQ INGN) opened at $129.09 on Friday. Inogen has a 1 year low of $73.68 and a 1 year high of $134.97. The firm has a market capitalization of $2,723.15, a price-to-earnings ratio of 135.88, a P/E/G ratio of 3.59 and a beta of 1.03.
TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/03/18/inogen-inc-ingn-given-consensus-rating-of-buy-by-brokerages.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.